

**MINUTE
AREA DRUG AND THERAPEUTICS COMMITTEE
WEDNESDAY 15th June 2022 @10am
Microsoft Teams Meeting**

In Attendance:

Dr Mehrdad Malekian	Mrs Karen Patterson	Ms Ann Auld
Mr George Lindsay (till 11am)	Dr Stephanie Dundas (till 11am)	Mr John Milne
Dr David Semple	Dr Tyra Smyth (from 11am)	Mrs Emma Harris
Mrs Gail Richardson	Mrs Penny Brankin	Dr Iain Hathorn

Mr Philippe Ghibu
(Item 3d)

2022/90	1.	<p><u>Apologies for Absence</u></p> <p>Mrs Christine Gilmour, Mrs Carol McGoff, Mrs Katrina Maroni, Mr Bill Angus, Mrs Linda Johnstone.</p>	
2022/91	2.	<p><u>Declaration of Interest</u></p> <p>There were no declarations of interest.</p>	
2022/92	3.	<p><u>Matters arising not covered elsewhere on the agenda</u></p> <p>a. <u>Ratification of minutes of meeting 18th May 2022</u></p> <p>The minute was accepted as a true record and can now be published.</p> <p>b. <u>Steroid Emergency Cards</u></p> <p>Mrs Richardson will contact Mrs Gilmour to request that the letter coming from Dr Burns be shared with the Pharmacy Heads of Department.</p> <p>It was noted that there is a request from the ADTCC for Health Boards to nominate members for a SLWG which will consider how prescribing data can be analysed to help target the steroid cards to patients who may benefit.</p> <p>c. <u>A guideline for Periprocedure management of coagulation.</u></p> <p>This will come back to a future meeting.</p>	GR

	<p>d. <u>Catheter Directed Thromolysis</u></p> <p>Mr Philippe Ghibu was in attendance for this item and he gave a thorough explanation of the rationale for this technique including his experience with it at St Thomas Hospital in London. The guideline draws heavily from that experience.</p> <p>There was clarity that the ADTC approval relates to the medication aspects of the protocol, including the use outwith licence of alteplase, and there was agreement that this is approved subject to a review of</p> <ul style="list-style-type: none"> • some typographical issues • feedback on fine points of detail from Mrs Richardson • a check for consistency with other related guidelines <p>Dr Malekian will work with Mr Ghibu to manage this and to agree suitable communication across a range of multidisciplinary stakeholders.</p> <p>e. <u>NHS Lanarkshire Vasculitis Protocol</u></p> <p>This will come back to a future meeting.</p> <p>f. <u>PGD Review Date Process</u></p> <p>Mr Lindsay reported on discussions which are ongoing.</p> <p>g. <u>Community optometrist initiation of aspirin for TIA</u></p> <p>Mr Lindsay reported that in response to a question at the May ADTC there are no other Health Boards currently replicating our plans but there is interest in doing so. He also reported that meetings with Mr Munro, Mr Lindsay, Prof Brankin and Prof Barber with regard to training are organised.</p>	GR MM
2022/93 4.	<p><u>SMC Advice</u></p> <p><u>FULL SUBMISSIONS</u></p> <p>Solriamfetol (Sunosi®) SMC2439</p> <p>This was noted and will be referred to neurology.</p> <p>Crizanlizumab (Adakveo®) SMC2438</p> <p>This was noted and will be referred to haematology.</p>	

	<p><u>NON SUBMISSIONS</u></p> <p>Enfortumab vedotin (Padcev®) SMC2505</p> <p>This was noted.</p> <p>Vedolizumab (Entyvio®) SMC2506</p> <p>This was noted.</p> <p><u>Update on the interim assessment approach in response to COVID-19</u></p> <p><u>FULL SUBMISSIONS</u></p> <p>Pegcetacoplan 1,080mg solution for infusion (Aspaveli®) SMC2451</p> <p>This was noted and will be referred to Dr Lindsay Mitchell.</p> <p>Delafloxacin 450mg tablets and 300mg powder for concentrate for solution for infusion (Quofenix®) SMC2453</p> <p>This was noted and will be referred to Dr Dundas</p> <p><u>DEFERRED ADVICE</u></p> <p>Odevixibat 200, 400, 600 and 1,200 microgram hard capsules (Bylvay®) SMC2411</p> <p>This was noted.</p> <p><u>AMENDED ADVICE</u></p> <p>Tepotinib 225mg film-coated tablets (Tepmetko®) SMC2457</p> <p>This was noted</p> <p><u>PAEDIATRIC EXTENSIONS</u></p> <p>This was noted.</p>	<p>CMcG/ KM</p>
<p>2022/94 5.</p>	<p><u>SMC follow up</u></p> <p>This was noted.</p>	<p>CMcG</p>

<p>2022/95 6.</p> <p>a.</p> <p>b.</p>	<p><u>Lanarkshire Formulary</u></p> <p>Potential for Appeals Process for Gluten Free Foods Formulary</p> <p>Mr Lindsay talked through a case study which illustrated some issues with regards amendments to the GFF Formulary. There was a full discussion which concluded that we should not introduce an appeals process between annual updates but we can work on systems to include patient feedback at the annual reviews.</p> <p>Mr Lindsay will respond to the patient with this explanation.</p> <p>June Formulary Amendments</p> <p>The recommendations submitted by Mrs McGoff were approved</p>	<p>GL</p> <p>CMcG</p>
<p>2022/96 7.</p> <p>a.</p> <p>b.</p> <p>c.</p>	<p><u>Clinical Protocols</u></p> <p><u>Dapagliflozin</u></p> <p>The submission is incomplete at this stage. Further information is required with respect to doses. Canagliflozin is also mentioned but this is not used in CKD. We are not aware of any pharmacy input into the submission and Primary Care representation will also be required.</p> <p>Dr Malekian will feedback to the author.</p> <p><u>ADTC submission for potassium lowering drugs</u></p> <p>This submission is incomplete at this stage. A separate protocol will be required for each medicine. Both eGFR and CrCl are mentioned in the documents but there should be a consistency for the preferred system and pharmacy input should be sought for the next draft.</p> <p>Dr Malekian will feedback to the author.</p> <p><u>Liraglutide</u></p> <p>This submission is incomplete at this stage. Pharmacy input should be sought for the next draft which should also clarify an inconsistency between the BMI referenced in the submission and that within the SmPC.</p> <p>Clarity and agreement about ongoing prescribing and monitoring is required with input from Primary Care which should also detail supplies of sundries such as needles.</p> <p>Dr Malekian will feedback to the author.</p>	<p>MM</p> <p>MM</p> <p>MM</p>

	<p>d. <u>Filgotinib</u></p> <p>This protocol was approved.</p> <p>Dr Malekian will feedback to the author.</p> <p>e. <u>Emergency (RESCUE) seizure medication</u></p> <p>There was useful discussion around the following themes:</p> <ul style="list-style-type: none"> • Supply systems, quantities and GP responsibility • The acceptability of the the forms by care organisations • Terminology relating to guidelines and policy. <p>Mrs Richardson will feedback to the paediatric pharmacist at UHW to consider these issues and make changes as appropriate.</p>	<p>MM</p> <p>GR</p>
<p>2022/97 8.</p>	<p><u>ADTC New Medicines Decisions</u></p> <p>This was noted.</p>	<p>CMcG</p>
<p>2022/98 9.</p> <p>a.</p> <p>b.</p>	<p><u>Unlicensed Medicines</u></p> <p>Monkeypox Vaccine</p> <p>It was agreed that the governanace systems regarding the use of monkeypox vaccine are strong and subject to frequent national update. For that reason its use in accordance with national updates and the NHS Lanarkshire Monkeypox IMT/PAG was agreed.</p> <p>Faecal Microbiota Transplant</p> <p>Dr Dundas explained this issue and it was agreed that the University of Brimingham product be used in NHS Lanarkshire and that the paperwork submitted with the request be used locally.</p> <p>Dr Dundas explained how the screening processes currently in place and agreed to compare this with the screening processes for the University of Birmingham supply to give assurance that the current standards will continue to be met.</p>	<p>GL</p> <p>SD</p>
<p>2022/99 10.</p>	<p><u>Patient Group Directions</u></p> <p>There were no submissions for today's meeting</p>	
<p>2022/100 11.</p>	<p><u>Medication and Clinical risk in Lanarkshire</u> https://www.gov.uk/drug-safety-update</p> <p>This was noted.</p>	

2022/101 12.	<p><u>Regional Cancer Advisory Network</u></p> <p>There was nil to note at today's meeting.</p>	
2022/102 13.	<p><u>Patient Safety Alerts</u></p> <p>There was nil to note at today's meeting.</p>	
2022/103 14.	<p><u>Lay member related items</u></p> <p>There was nil to note at today's meeting.</p>	
2022/104 15.	<p><u>ADTCC Correspondence</u></p> <p>a.</p> <p>Update to 'Guidance for Repurposing Prescription Only Medicines (POMs) in Care Homes and Hospices during the COVID-19 pandemic</p> <p>This was welcomed.</p> <p>b.</p> <p>Sodium Valproate Learning System: Call for Nominees</p> <p>A pharmacist at UHW may be interested in joining this group. Mrs Richardson will feedback.</p>	GL
2022/105 16.	<p>Pharmacy & NMAHP Prescribing Governance</p> <p>There was nil to note at todays meeting.</p>	PB
2022/106 17.	<p><u>AOCB</u></p> <p>There was nil to note at todays meeting.</p>	
2022/107 18.	<p><u>Date of next meeting</u></p> <p>Wednesday 20th July 2022 10am @ Microsoft Teams</p>	